{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:58:36Z","timestamp":1776247116983,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>FOLFIRINOX is a first-line treatment option for patients with metastatic pancreatic cancer (MPC) and is associated with improved survival yet significantly more toxicities than standard gemcitabine. Our aim was to determine the proportion of patients with MPC who would be eligible for FOLFIRINOX based upon the pivotal ACCORD study criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with confirmed MPC at the time of referral to the BC Cancer Agency between 2004 and 2007 were identified from the Gastrointestinal Cancers Outcomes Unit Database (GICOU). Proportion of patients that met the ACCORD study eligibility criteria was determined by chart review. Criteria for FOLFIRINOX exclusion were assessed using descriptive statistics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 100 consecutive patients with complete chart records and MPC were identified. Fifty-two (52%) were male and the median age was 68 years (range, 42 to 98 y). The most common sites of metastases were liver (63%) and peritoneum (22%). Only 26 patients fulfilled the ACCORD study eligibility criteria. The most common reasons for FOLIFIRINOX exclusion per ACCORD were poor Eastern Cooperative Oncology Group score of \u22652 (64%), age of 76 years or greater (22%), elevated bilirubin (22%), and inadequate renal function (6%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Despite the proven survival benefit of FOLFIRINOX, only approximately one quarter of patients in the real-world setting with MPC would have been considered eligible for such therapy based upon the ACCORD eligibility criteria. Careful patient selection and more tolerable therapies are required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000205","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T21:32:43Z","timestamp":1436650363000},"page":"552-554","source":"Crossref","is-referenced-by-count":16,"title":["Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia"],"prefix":"10.1097","volume":"40","author":[{"given":"Maria Yi","family":"Ho","sequence":"first","affiliation":[{"name":"Divison of Medical Oncology, Cross Cancer Institute, Edmonton, AB"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagen F.","family":"Kennecke","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Renouf","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard J.","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience","volume":"18","author":"Faris","year":"2013","journal-title":"Oncologist"},{"issue":"suppl","key":"R7-20230903","first-page":"e14614","article-title":"Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxalipltain (FOLFIRINOX) in patients with pancreatic cancer (PCA)","volume":"30","author":"Goncalves","year":"2012","journal-title":"ASCO Meet Abstr"},{"issue":"suppl","key":"R8-20230903","first-page":"e14614","article-title":"Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: a retrospective experience","volume":"30","author":"Mahaseth","year":"2012","journal-title":"ASCO Meet Abstr"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12032-012-0361-2","article-title":"FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity","volume":"30","author":"Gunturu","year":"2013","journal-title":"Med Oncol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bjc.6602640","article-title":"Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)","volume":"93","author":"Di Costanzo","year":"2005","journal-title":"Br J Cancer"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer","volume":"24","author":"Heinemann","year":"2006","journal-title":"J Clin Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-013-2239-1","article-title":"A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer","volume":"72","author":"Chao","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6603301","article-title":"A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer","volume":"95","author":"Stathopoulos","year":"2006","journal-title":"Br J Cancer"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","article-title":"Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Poplin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201712000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:06:44Z","timestamp":1693710404000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201712000-00004"}},"subtitle":["A Population-based Retrospective Study"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000205","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}